Key points are not available for this paper at this time.
Patients with CF from minority groups are less likely to be eligible for CFTR modulators. Because people with CF who are racial and ethnic minorities have increased disease severity and earlier mortality, this will further contribute to health disparities.
McGarry et al. (Wed,) studied this question.